Key Points
- Inogen EVP Boyer Jennifer Yi sold 10,770 shares on May 29 at an average price of $6.53, totaling about $70,328. Following the sale, she held 15,977 shares, a 40.27% reduction in her position.
- Inogen recently reported quarterly EPS of ($0.30), missing analyst expectations of ($0.24), though revenue of $85.11 million came in above forecasts. Analysts currently expect the company to post -0.77 EPS for the full year.
- The stock opened at $6.09, near its 52-week low of $5.34, and analysts’ views are mixed, with a consensus rating of Moderate Buy and an average price target of $14.00.
Inogen, Inc (NASDAQ:INGN - Get Free Report) EVP Boyer Jennifer Yi sold 10,770 shares of the firm's stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $6.53, for a total value of $70,328.10. Following the transaction, the executive vice president directly owned 15,977 shares in the company, valued at approximately $104,329.81. This represents a 40.27% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Inogen Price Performance
NASDAQ INGN opened at $6.09 on Wednesday. Inogen, Inc has a 52-week low of $5.34 and a 52-week high of $9.13. The business's 50-day moving average price is $6.60 and its 200 day moving average price is $6.49. The firm has a market cap of $164.92 million, a P/E ratio of -6.69 and a beta of 1.60.
Inogen (NASDAQ:INGN - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The medical technology company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.06). Inogen had a negative return on equity of 12.90% and a negative net margin of 7.08%.The company had revenue of $85.11 million for the quarter, compared to analysts' expectations of $82.35 million. As a group, analysts anticipate that Inogen, Inc will post -0.77 earnings per share for the current year.
Analyst Ratings Changes
A number of equities research analysts have weighed in on INGN shares. Freedom Capital raised Inogen to a "strong-buy" rating in a report on Tuesday, April 7th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Inogen in a report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $14.00.
View Our Latest Stock Report on Inogen
Institutional Investors Weigh In On Inogen
A number of institutional investors have recently added to or reduced their stakes in the business. Quarry LP purchased a new stake in shares of Inogen during the 4th quarter worth approximately $27,000. Torren Management LLC purchased a new stake in shares of Inogen during the 4th quarter worth approximately $51,000. Prelude Capital Management LLC purchased a new stake in shares of Inogen during the 3rd quarter worth approximately $82,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Inogen during the 3rd quarter worth approximately $90,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in shares of Inogen during the 1st quarter worth approximately $85,000. Hedge funds and other institutional investors own 89.94% of the company's stock.
Inogen Company Profile
(
Get Free Report)
Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company's core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen's offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.
Inogen's flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
